Comparing Botox and Xeomin for axillar hyperhidrosis
- PMID: 20143241
- DOI: 10.1007/s00702-010-0372-0
Comparing Botox and Xeomin for axillar hyperhidrosis
Abstract
Recently, Xeomin, a novel botulinum toxin (BT) type A drug became available. Separation of complexing proteins reduced the size of its BT component, thus potentially affecting its tissue diffusion, adverse effect profile and therapeutic properties. We report the first use of Xeomin in an autonomic indication. A total of 46 patients (34 females, 12 males, age 32.7 +/- 13.2 years, disease duration 14.2 +/- 12.0 years) with symmetric bilateral idiopathic axillar hyperhidrosis and a previously stable Botox treatment received 50 MU of BT in 5 ml of 0.9% NaCl/H(2)0 in each axilla. The patient, the injector and the observer were unaware of which axilla received Xeomin and which Botox. The therapeutic effect as measured from the BT application to the onset of its decrease lasted 3.2 +/- 1.4 months and was excellent in 89% and good in 11% of the patients. Side-to-side differences of the therapeutic effect (onset latency, extent, duration) were neither detectable by the patient nor by the physician. Injection site pain was identical and adverse effects did not occur. Xeomin can be used safely and effectively for the treatment of axillar hyperhidrosis. Size differences between Xeomin and Botox do not affect their therapeutic efficacy, tissue diffusion and adverse effect profile. Identical potency labelling allows easy exchange between both products.
Similar articles
-
Routine use of Xeomin in patients previously treated with Botox: long term results.Eur J Neurol. 2009 Dec;16 Suppl 2:2-5. doi: 10.1111/j.1468-1331.2009.02877.x. Eur J Neurol. 2009. PMID: 20002739 Clinical Trial.
-
Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox(®) doses.J Neural Transm (Vienna). 2013 Nov;120(11):1565-7. doi: 10.1007/s00702-013-1021-1. Epub 2013 Jun 14. J Neural Transm (Vienna). 2013. PMID: 23764912
-
Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.J Drugs Dermatol. 2011 Sep;10(9):1013-5. J Drugs Dermatol. 2011. PMID: 22052270 Review.
-
Botulinum toxin type B for treatment of axillar hyperhidrosis.J Neurol. 2002 Dec;249(12):1729-32. doi: 10.1007/s00415-002-0929-4. J Neurol. 2002. PMID: 12529798
-
[Pharmacological aspects of therapeutic botulinum toxin preparations].Nervenarzt. 2006 Aug;77(8):912-21. doi: 10.1007/s00115-006-2090-2. Nervenarzt. 2006. PMID: 16810528 Review. German.
Cited by
-
Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature.Toxins (Basel). 2022 May 27;14(6):372. doi: 10.3390/toxins14060372. Toxins (Basel). 2022. PMID: 35737033 Free PMC article. Clinical Trial.
-
[Botulinum toxin in focal hyperhidrosis. An update].Hautarzt. 2012 Jun;63(6):469-76. doi: 10.1007/s00105-012-2333-z. Hautarzt. 2012. PMID: 22638981 Review. German.
-
Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.J Neural Transm (Vienna). 2018 Sep;125(9):1351-1354. doi: 10.1007/s00702-018-1897-x. Epub 2018 Jun 26. J Neural Transm (Vienna). 2018. PMID: 29946929
-
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.J Neurol. 2013 Mar;260(3):701-13. doi: 10.1007/s00415-012-6615-2. Epub 2012 Aug 10. J Neurol. 2013. PMID: 22878428
-
Onabotulinumtoxin type A (Botox(®)) versus Incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial.J Neural Transm (Vienna). 2014 Jan;121(1):21-6. doi: 10.1007/s00702-013-1074-1. Epub 2013 Sep 20. J Neural Transm (Vienna). 2014. PMID: 24052109 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials